Drug Profile
GSK 3179106
Alternative Names: GSK3179106Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Irritable bowel syndrome therapies
- Mechanism of Action Proto oncogene protein c ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Irritable bowel syndrome
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome(In volunteers) in Australia (PO, Tablet)
- 01 Nov 2016 GlaxoSmithKline completes a phase I trial in Healthy volunteers in Australia (NCT02798991)
- 17 Jun 2016 GlaxoSmithKline plans a phase I trial in Healthy volunteers in Australia (NCT02798991)